Research progress of adjuvant TACE therapy for liver cancer after radical resection.
10.3760/cma.j.cn501113-20200609-00302
- Author:
Zhi Cheng JIN
1
;
Qi ZHANG
2
;
Hai Dong ZHU
2
;
Gao Jun TENG
3
Author Information
1. Southeast University School of Medicine, Nanjing 210009, China.
2. Center of Interventional Radiology and Vascular Surgery, Department of Radiology, Zhongda Hospital, Medical School, Southeast University, Nanjing 210009, China.
3. Southeast University School of Medicine, Nanjing 210009, China Center of Interventional Radiology and Vascular Surgery, Department of Radiology, Zhongda Hospital, Medical School, Southeast University, Nanjing 210009, China.
- Publication Type:Review
- MeSH:
Carcinoma, Hepatocellular/pathology*;
Chemoembolization, Therapeutic/methods*;
Hepatectomy;
Humans;
Liver Neoplasms/pathology*;
Neoplasm Recurrence, Local/pathology*;
Retrospective Studies
- From:
Chinese Journal of Hepatology
2022;30(3):340-344
- CountryChina
- Language:Chinese
-
Abstract:
Transcatheter arterial chemoembolization (TACE) is the most commonly used method for non-surgical treatment of liver cancer, and it is usually used as an adjuvant therapy in patients who have not developed intrahepatic metastases after surgical resection. Postoperative adjuvant TACE therapy may provide a prognostic benefit in liver cancer patients with high recurrence risk. This article reviews the research progress of adjuvant TACE therapy for liver cancer after radical resection.
